Bausch Health Companies Inc. (TSE:BHC - Get Free Report)'s share price reached a new 52-week high during trading on Wednesday . The company traded as high as C$15.43 and last traded at C$13.55, with a volume of 362608 shares traded. The stock had previously closed at C$13.83.
Analyst Ratings Changes
Separately, Royal Bank of Canada boosted their price target on shares of Bausch Health Companies from C$8.00 to C$9.00 and gave the company a "sector perform" rating in a report on Friday, February 23rd.
View Our Latest Stock Report on Bausch Health Companies
Bausch Health Companies Stock Down 1.7 %
The firm has a market cap of C$4.97 billion, a price-to-earnings ratio of -6.18, a P/E/G ratio of 0.21 and a beta of 0.83. The firm's fifty day moving average is C$12.22 and its two-hundred day moving average is C$10.94. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.30 and a quick ratio of 0.58.
Bausch Health Companies (TSE:BHC - Get Free Report) last issued its quarterly earnings results on Thursday, February 22nd. The company reported C$1.55 EPS for the quarter, topping the consensus estimate of C$1.36 by C$0.19. Bausch Health Companies had a negative net margin of 6.76% and a negative return on equity of 686.52%. The firm had revenue of C$3.28 billion for the quarter, compared to analysts' expectations of C$3.05 billion. On average, sell-side analysts expect that Bausch Health Companies Inc. will post 4.9653979 EPS for the current fiscal year.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
